A Modified Protocol for Myocardial Perfusion SPECT Using Natural Plant Extracts for Enhancement of Biliorg Excretion

담즙분비촉진 식물추출물을 이용한 심근관류영상 검사법 개선

  • Jeong, Hwan-Jeong (Department of Nuclear Medicine, Wonkwang University School of Medicine) ;
  • Kim, Chang-Guhn (Department of Nuclear Medicine, Wonkwang University School of Medicine)
  • 정환정 (원광대학교 의과대학 핵의학교실) ;
  • 김창근 (원광대학교 의과대학 핵의학교실)
  • Published : 2003.12.30

Abstract

Purpose: For good quality of myocardial perfusion images, an approximately 30 min to 1 hour of waiting time after radiopharmaceutical injection and ingestion of fatty meal are asked of the patients. The aim of this study was to investigate the shortening of waiting time after radiopharmaceutical injection and improvement of image quality using natural plant extracts that promote bile excretion. Materials and Methods: Ten volunteers participated in protocol 1 (7 men, 3 women; mean age, $24.1{\pm}2.4$ years) and protocol 2 (8 men, 2 women; mean age, $26.1{\pm}2.9$ years), respectively. For the modified method of both protocols, subjects took natural plant extracts 15 minutes before the first injection of $^{99m}Tc$ MIBI without laking fatty meals. Control (Conventional) methods were peformed with intake of a fatty meal 20 to 30 minutes after $^{99m}Tc$ MIBI injection. Results: As the results of protocol 1 and 2, the ratio of myocardial to lung ratio were not different between modified and conventional method. Liver to lung ratio of modified method showed significantly lower value than that of conventional method. In modified method, myocardial to liver ratio was higher persistently. In protocol 2, natural plant extracts took before the first injection of $^{99m}Tc$ MIBI exerted accelerating effect of excretion of bile juice into Intestine until the end of examination. Conclusion: These results represent that natural plant extracts for facilitation of bile excretion before injection of $^{99m}Tc$ MIBI may provide better quality of myocardial perfusion images without the need for preparations such as ingestion of fatty meal within the 2 hours compared with conventional method.

목적: 심근관류 영상은 관상동맥 질환을 진단하고 환자의 예후를 평가하는데 널리 사용되고 있다. $^{99m}Tc$ 제재를 이용한 심근관류 영상은 간 방사능을 줄이고 좋은 영상을 얻기 위해 주사 후 일정시간을 대기하고, 지방식을 섭취하는 검사방법을 사용하고있다. 이번 연구에서는 식물 추출물 혼합제재를 이용하여 간 방사능의 배출을 촉진함으로써 검사시간을 단축시키고, 심근영상의 질을 향상시킬 수 있는지 알아보고자 하였다. 대상 및 방법: 프로토콜 1은 식물추출물의 환약제재(이하 혼합제재)를 투여한 개선법이 간 방사능의 배출을 촉진하고 영상의 질을 향상시키는 지 알아보기 위해 건강하고 젊은 자원자 10명(남: 녀=7: 3, 평균 연령 $24.1{\pm}2.4$세)을 대상으로 혼합제재를 복용하고 15분 후 MIBI를 주사하였으며, 주사 후 30분, 60분, 90분, 그리고 120분째 영상을 얻어 분석하였다. 프로토콜 2는 $^{99m}Tc$ 심근관류 영상법에서 널리 이용되고 있는 1일 휴식-부하방법에 혼합제재를 사용하였을 때의 개선법의 효과를 알아보기 위해 다른 자원자 10명(남: 녀=8: 3, 평균 연령 $26.1{\pm}2.9$세)을 대상으로 개선법과 고식적 방법(우유와 아이스크림 등 지방식 투여)을 적용한 영상을 얻어 분석하였다. 결과: 프로토콜 1에서 개선법과 고식적 방법의 심근/폐 방사능 비는 90분 영상까지 유의한 차이를 보이지 않았으며, 간/폐 방사능 비는 120분 영상까지 개선법이 고식적 방법에 비해 유의하게 낮은 값을 보였다. 심근/간 방사능 비는 개선법에서 지속적으로 높은 값을 보였다. 프로토콜 2에서 첫 번째 MIBI를 주사한 후 심근/페 방사능은 유의한 차이가 없었으나 심근/간 방사능비는 45분과 60분 영상에서 개선법이 유의하게 높은값을 보였다. 두 번째 MIBI를 주사한 후에는 20분 영상부터 지속적으로 개선법의 심근/간 방사능 비가 높은 값을 보였으나, 첫 번째 주사와 마찬가지로 심근/폐 방사능 비는 차이가 없었다. 결론: 담즙 배출을 촉진하는 천연식물 추출 혼합제재를 심근관류 영상을 획득하는데 적용하면 지방식 섭취없이 검사 소요 시간을 2시간대로 단축시킬 수 있어 환자의 불편을 최소화시키면서 영상의 질을 향상시킨 수 있을 것으로 판단된다.

Keywords

References

  1. Yaoita H, Strauss HW. Role of single photon wall motion and perfusion studies in the evaluation of patients with suspected coronary artery disease. Eur J Nucl Med 1990;17:269-78 https://doi.org/10.1007/BF00812369
  2. Franceschi M, Guimond J, Zimmerman RE, Picard MV, English RJ, Carvalho PA, et al. Myocardial clearance of Tc-99m hexakis-2-methoxy-2-methylpropyl isonitrile (MIBI) in patients with coronary artery disease. Clin Nucl Med 1990;15:307-12 https://doi.org/10.1097/00003072-199005000-00005
  3. Gregoire J, Theroux P. Detection and assessment of unstable angina using myocardial perfusion imaging: comparison between technetium-99m sestamibi SPECT and 12-lead electrocardiogram. Am J Cardiol 1990;66:42E-46E https://doi.org/10.1016/0002-9149(90)90611-4
  4. Maddahi J, Kiat H, Van Train KF, Prigent F, Friedman J, Garcia EV, et al. Myocardial perfusion imaging with technetium-99m sestamibi SPECT in the evaluation of coronary artery disease. Am J Cardiol 1990;66:55E-62E https://doi.org/10.1016/0002-9149(90)90613-6
  5. Najm YC, Timmis AD, Maisey MN, Ellam SV, Mistry R, Curry PV, et al. The evaluation of ventricular function using gated myocardial imaging with Tc-99m MIBI. Eur Heart J 1989;10:142-8 https://doi.org/10.1093/eurheartj/10.suppl_F.142
  6. Villanueva-Meyer J, Mena I, Narahara KA. Simultaneous assessment of left ventricular wall motion and myocardial perfusion with technetium- 99m-methoxy isobutyl isonitrile at stress and rest in patients with angina: comparison with thallium-201 SPECT. J Nucl Med 1990;31:457-63
  7. Jones RH, Borges-Neto S, Potts JM. Simultaneous measurement of myocardial perfusion and ventricular function during exercise from a single injection of technetium-99m sestamibi in coronary artery disease. Am J Cardiol 1990;66:68E-71E https://doi.org/10.1016/0002-9149(90)90615-8
  8. Savi A, Gerundini P, Zoli P, Maffioli L, Compierchio A, Colombo F, et al. Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. Eur J Nucl Med 1989;15:597-600
  9. Inoue Y, Machida K, Honda N, Mamiya T, Takahashi T, Kamano T, Kashimada A. Clearance of 99mTc-Tetrofosmin from the myocardium and the adjacent organs. Kaku Igaku 1993;30:313-6
  10. Rigo P, Leclercq B, Itti R, Lahiri A, Braat S. Technetium-99m-tetrofosmin myocardial imaging: a comparison with thallium-201 and angiography. J Nucl Med 1994;35:587-93
  11. Higley B, Smith FW, Smith T, Gemmell HG, Das Gupta P, Gvozdanovic DV, et al. Technetium- 99m-1,2-bis[bis(2-ethoxyethyl) phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med 1993;34:30-8
  12. Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokinetics of technetium- 99m-tetrofosmin: myocardial perfusion imaging agent: implications for a one-day imaging protocol. J Nucl Med 1993;34:1254-9
  13. Kelly JD, Forster AM, Higley B, Archer CM, Booker FS, Canning LR, et al. Technetium- 99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993;34:222-7
  14. Maddahi J, Kiat H, Van Train KF, Prigent F, Friedman J, Garcia EV, et al. Myocardial perfusion imaging with technetium-99m sestamibi SPECT in the evaluation of coronary artery disease. Am J Cardiol 1990;66:55E-62E https://doi.org/10.1016/0002-9149(90)90613-6
  15. Haronian HL, Remetz MS, Sinusas AJ, Baron JM, Miller HI, Cleman MW, et al. Myocardial risk area defined by technetium-99m sestamibi imaging during percutaneous transluminal coronary angioplasty: comparison with coronary angiography. J Am Coll Cardio. 1993;22:1033-43 https://doi.org/10.1016/0735-1097(93)90413-U
  16. Matsunari I, Fujino S, Taki J, Senma J, Aoyama T, Wakasugi T, et al. Quantitative rest technetium-99m tetrofosmin imaging in predicting functional recovery after revascularization: comparison with rest-redistribution thallium-201. J Am Coll Cardiol 1997;29:1226-33 https://doi.org/10.1016/S0735-1097(97)00061-2
  17. Zanco P, Zampiero A, Favero A, Borsato N, Chierichetti F, Rubello D, et al. Myocardial technetium-99m sestamibi single-photon emission tomography as a prognostic tool in coronary artery disease: multivariate analysis in a long-term prospective study. Eur J Nucl Med 1995;22:1023-8 https://doi.org/10.1007/BF00808414
  18. Montz R, Perez-Castejon MJ, Jurado JA, Martin-Comin J, Esplugues E, Salgado L, et al. Technetium-99m tetrofosmin rest/stress myocardial SPET with a same-day 2-hour protocol: comparison with coronary angiography. A Spanish-Portuguese multicentre clinical trial. Eur J Nucl Med 1996;23:639-47 https://doi.org/10.1007/BF00834525